Cameron recently completed his Ph.D. in Biomedical Sciences at the University of California – San Francisco. Under biotech research pioneer Frank McCormick, his research focused on functional differences in oncogenic mutations in KRAS, the most common driver oncogene in human cancer. His work had a translational component aimed toward direct inhibition of KRAS proteins once thought to be undruggable. While working on his Ph.D., he also collaborated on a breast cancer drug development program at Genentech. Cameron was a UCSF Moritz-Heyman Discovery Fellow and a NSF Graduate Research Fellow.
Cameron earned his B.S. in Biology from Stanford University, where he was awarded research training fellowships at the NIH – NICHD.